Serum Paraoxonase / Arylesterase 1 (PON1) Antibody

Product Graph
383.5€ (100 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Serum Paraoxonase / Arylesterase 1 (PON1) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx016096
tested applications
ELISA, WB, IHC, IF/ICC, FCM

Description

PON1 Antibody is a Mouse Monoclonal against PON1.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Target: Serum Paraoxonase / Arylesterase 1 (PON1)
Immunogen: Purified recombinant fragment of human PON1 (AA: 20-155) expressed in E. coli.
Host
Mouse
Reactivity
Human
Assay Type
Concentration: 1 mg/ml
Recommended Dilution
ELISA: 1/10000, WB: 1/500 - 1/2000, IHC: 1/200 - 1/1000, IF/ICC: 1/200 - 1/1000, FCM: 1/200 - 1/400. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Monoclonal
Conjugation
Unconjugated
Isotype
IgG1
Observed MW
39.7 kDa
Purification
Purified from ascites by Protein G chromatography.
Size 1
100 µl
Form
Liquid
Tested Applications
ELISA, WB, IHC, IF/ICC, FCM
Buffer
PBS, containing 0.05% sodium azide.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P27169
Gene ID
5444
OMIM
168820
Background
Antibody anti-PON1
Status
RUO
Note
THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Descripción

Related Products

EH0257

Human PON1 (Serum paraoxonase/arylesterase 1) ELISA Kit

Ver Producto
ER0265

Rat Pon1 (Serum paraoxonase/arylesterase 1) ELISA Kit

Ver Producto
FNab06638

PON1 antibody

Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation.

Ver Producto